Chen Chen

Chen represents public and private life sciences companies in strategic licensing and collaboration transactions, including discovery and research collaborations, option agreements, co-development and co-commercialization arrangements, and territory-specific agreements. She is experienced in cross-border transactions involving inbound or outbound licenses or joint ventures. She also counsels life sciences clients on day-to-day operational matters such as vendor services, manufacturing and supply, sponsored research, and clinical trials.

Chen’s recent matters include representing:

• Merus in its research collaboration with Biohaven to co-develop three novel bispecific antibody-drug conjugates (ADCs) leveraging Merus’ leading antibody technology platform and Biohaven’s ADC conjugation and payload platform technologies (2025)
• Avenzo Therapeutics in its agreement with Duality Biotherapeutics to obtain global rights (excluding Greater China) for DB-1418, an epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 3 (HER3) bispecific ADC (2025)
• Kura Oncology in its global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor, with profit-sharing in the US (2024)
• Radionetics Oncology in its strategic collaboration with Eli Lilly to develop Radionetics’ proprietary G protein-coupled receptor-targeting small molecule radiopharmaceuticals, with an option for Lilly to acquire Radionetics upon conclusion of an exercise period (2024)
• OrbiMed in a newly formed company transaction (Belenos Biosciences) with Keymed Biosciences for exclusive global rights (excluding Greater China) for CM512 and CM536, Keymed’s proprietary bispecific antibodies (2024)
• SystImmune in its global collaboration with Bristol Myers Squibb to develop and commercialize BL-B01D1, SystImmune’s novel EGFR/HER3 bispecific ADC, with profit-sharing in the US (2023)
• MediLink Therapeutics in its strategic collaboration with BioNTech to license MediLink’s proprietary ADC directed to HER3, with MediLink retaining rights in Greater China (2023)
• Genomatica in its joint venture with Unilever to commercialize and scale plant-based alternatives to feedstocks like palm oil and fossil fuels to make key ingredients used in everyday cleaning and personal care products (2022)